Anika Therapeutics, Inc.
Anika Therapeutics, Inc.
Your view on ANIK
Overview
What the company does, where it operates, and who runs it.
About Anika Therapeutics, Inc.
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Cheryl Renee Blanchard
- Headquarters
- 32 Wiggins Avenue, Bedford, MA, US
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Cheryl Renee Blanchard
- Headquarters
- 32 Wiggins Avenue, Bedford, MA, US
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.
The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.
Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products.
The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Anika Therapeutics, Inc., and the rating behind it. ANIK last traded at $20.99; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Anika Therapeutics, Inc.. Starting points for Anika Therapeutics, Inc.: EPS -$0.28, beta 0.20 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Anika Therapeutics, Inc.. Anika Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Anika Therapeutics, Inc.. Trailing twelve-month EPS for Anika Therapeutics, Inc. stands at -$0.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Anika Therapeutics, Inc.. Anika Therapeutics, Inc. has reported as a listed company since 1993. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Anika Therapeutics, Inc. valued side by side against its closest peers. Anika Therapeutics, Inc. is measured against Medical - Specialties peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Anika Therapeutics, Inc., and how their positions are changing. At a $280.9M market value, institutional positions materially move Anika Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Anika Therapeutics, Inc. executives and directors. Shares of Anika Therapeutics, Inc. have traded between $7.87 and $18.37 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Anika Therapeutics, Inc.. Anika Therapeutics, Inc. is a $280.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Anika Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Anika Therapeutics, Inc.. Coverage tracks Anika Therapeutics, Inc. within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.